Cat Oyler serves as Vice President, Global Public Health (GPH), leading the Tuberculosis (TB) Focus Area Strategy Team (FAST) and as a member of the GPH Executive Leadership Team. In this role, Cat leads the enterprise TB FAST to deliver on our aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis (MDR-TB). The TB FAST includes a dedicated cross-functional group of professionals representing marketing, market access, research & development, on-the-ground execution, external affairs and consumer programming.
Cat previously served as Global Head, Strategy & Operations for Johnson & Johnson Innovation (JJI). Cat had responsibility for strategy development and operational excellence for JJI, and for aligning the World Without Disease Accelerator, Lung Cancer Initiative and JJI organizations to accelerate innovation to prevent, intercept and cure disease.
Cat formerly held the role of Vice President, Strategy and External Innovation for Janssen Research and Development, the global R&D arm of the Janssen Pharmaceutical Companies of Johnson & Johnson. In that capacity, Cat led development and execution of long-term growth strategies for Janssen Research & Development. She served on Janssen R&D's Senior Leadership Team and its Investment Committee and managed the strategic reviews of the pharmaceutical R&D portfolio. Cat directed the development of the company's long-term "A World Without Disease" strategy, focusing on transforming human health by building the future capabilities necessary to prevent, intercept and cure disease. Cat also managed the development of Janssen R&D's China Innovation strategy.
Additionally, Cat is an Aspen Institute First Mover Fellow and serves as executive sponsor for the University workstream for WiSTEM2D (Women in Science Technology Engineering Math Manufacturing and Design). WiSTEM2D is a Johnson & Johnson initiative leveraging external partnerships to harness global communities, academic institutions and NGOs with a goal of building a diverse and healthy workforce for the future.
Cat joined Johnson & Johnson in 2008 in the Corporate Office of Science and Technology, then held a New Ventures role with J&J Innovation. Before joining Johnson & Johnson, Cat held business development roles at AstraZeneca and Myriad Genetics Inc., and marketing and scientist positions at Alza Corporation, Alkermes Inc., and Amgen Inc. She has a B.A. in Biology from Williams College and an MBA from the UCLA Anderson School of Management.